title: Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity.
authors.affiliation: Memorial Sloan Kettering Cancer Center, Gastrointestinal Oncology, 1275 York Avenue, Howard 910, New York, NY 10065, USA.
authors.forename: Timothy R
authors.initials: TR
authors.lastname: Asmis
authors.forename: Ki Y
authors.initials: KY
authors.lastname: Chung
authors.forename: Jerrold B
authors.initials: JB
authors.lastname: Teitcher
authors.forename: David P
authors.initials: DP
authors.lastname: Kelsen
authors.forename: Manish A
authors.initials: MA
authors.lastname: Shah
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D018278:Carcinoma, Neuroendocrine / Q000188:drug therapy / Q000556:secondary; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000473:pathology; D011006:Pneumatosis Cystoides Intestinalis / Q000139:chemically induced* / Q000175:diagnosis; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000276:immunology
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab